2 terminated, 1 completed. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 2, Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow atabecestat: new trials by email Literature Review of atabecestat trials Research Report on atabecestat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia Atabecestat, 5 mg, Atabecestat, 25 mg, Placebo - Asymptomatic Amyloid-positive | Phase 2 / Phase 3 | Terminated | Janssen Research & Development, LLC | 557 | 2015-10-29 | 2025-04-29 |
| An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum JNJ-54861911, 10 mg, JNJ-54861911, 25 mg, Placebo - Alzheimer Disease | Phase 2 | Terminated | Janssen Research & Development, LLC | 90 | 2015-07-02 | 2025-04-29 |
| A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease JNJ-54861911, 10 milligram (mg), JNJ-54861911, 50 mg, Placebo - Alzheimer's Disease | Phase 2 | Completed | Janssen Research & Development, LLC | 114 | 2014-11-01 | 2025-04-29 |
Alzheimer Disease (3) · Dementia (1)
Janssen Research & Development, LLC (3)
Belgium (3) · Germany (3) · Netherlands (3) · Spain (3) · Sweden (3) · France (2) · Australia (1) · Canada (1) · Denmark (1) · Finland (1) · Japan (1) · Mexico (1) · United Kingdom (1) · United States (1)
PMID 32410694, PMID 33464300, PMID 39559869
2014 (2), 2015 (1)